Crystal Structure
Crystallisation Method: EM
Corresponding Chain: A/C/E/G
Sequence Length: 76-620
Detail: Struture Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0513 | ||||
Gene Name | KCNQ1 | ||||
Protein Name | Voltage-gated potassium channel Kv7.1 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Crystal Structure Crystallisation Method: EM Corresponding Chain: A/C/E/G Sequence Length: 76-620 Detail: Struture Info |
||||
Synonyms | ATFB1; ATFB3; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; JLNS1; KCNA8; KCNA9; KCNQ1; KQT-like 1; KVLQT1; Kv1.9; Kv7.1; LQT; LQT1; RWS; SQT2; Potassium voltage-gated channel subfamily KQT member 1; WRS; Voltage-gated potassium channel subunit Kv7.1 | ||||
DT Family | Voltage-Gated Ion Channel (VIC) Superfamily ; | ||||
Tissue Specificity | Abundantly expressed in heart, pancreas,prostate, kidney, small intestine and peripheral blood leukocytes.Less abundant in placenta, lung, spleen, colon, thymus, testis andovaries. | ||||
Function | This potassium transporter associates with KCNE beta subunits and Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current. Promotes also a delayed voltage activated potassium current showing outward rectification characteristic. During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current. When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions. This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents. During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion. Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion. When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current. When associated with KCNE4, inhibits voltage-gated potassium channel activity. When associated with KCNE5, this complex only conducts current upon strong and continued depolarization. Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity. | ||||
Endogenous Substrate(s) | Potassium ions | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(α) Mutation-induced Structural Variation |
|||||
(β) Inter-species Structural Differences |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.